Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Accumulated Depreciation (2017 - 2025)

Historic Accumulated Depreciation for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Q2 2025 value amounting to $9.6 million.

  • Crinetics Pharmaceuticals' Accumulated Depreciation rose 5384.37% to $9.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was $9.6 million, marking a year-over-year increase of 5384.37%. This contributed to the annual value of $7.7 million for FY2024, which is 5256.51% up from last year.
  • According to the latest figures from Q2 2025, Crinetics Pharmaceuticals' Accumulated Depreciation is $9.6 million, which was up 5384.37% from $8.6 million recorded in Q1 2025.
  • Over the past 5 years, Crinetics Pharmaceuticals' Accumulated Depreciation peaked at $9.6 million during Q2 2025, and registered a low of $2.8 million during Q1 2021.
  • In the last 5 years, Crinetics Pharmaceuticals' Accumulated Depreciation had a median value of $4.6 million in 2023 and averaged $5.2 million.
  • As far as peak fluctuations go, Crinetics Pharmaceuticals' Accumulated Depreciation surged by 1695.04% in 2023, and later skyrocketed by 5772.18% in 2025.
  • Crinetics Pharmaceuticals' Accumulated Depreciation (Quarter) stood at $3.5 million in 2021, then grew by 17.36% to $4.1 million in 2022, then grew by 24.09% to $5.1 million in 2023, then surged by 52.57% to $7.7 million in 2024, then increased by 23.98% to $9.6 million in 2025.
  • Its Accumulated Depreciation was $9.6 million in Q2 2025, compared to $8.6 million in Q1 2025 and $7.7 million in Q4 2024.